Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...
(MENAFN- GetNews) The Key Prader-Willi Syndrome Companies in the market include - Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences, ACADIA Pharmaceuticals, ...
CHATHAM, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated commercial-stage biotechnology company with innovative marketed products and a ...
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients ...
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 ...
Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical ...
Harbaji, W. and Abdulai, A. (2025) Factors Influencing Schoolchildren’s Obesity: A Qualitative Document Analysis of ...
Treatment with intranasal carbetocin was not associated with a statistically significant improvement in hyperphagia compared with placebo. Topline results were announced from a phase 3 trial ...
SGLT2 inhibitors significantly improved glycaemic control and reduced the albumin-to-creatinine ratio without affecting body weight in patients with Prader-Willi syndrome and type 2 diabetes (T2D); ...
(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday said it plans to start a Phase 2 study of TNX-2900 for the treatment of Prader-Willi syndrome, a genetic disorder that affects multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback